+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Xalkori"

From
ALK-Positive Non-Small Cell Lung Cancer - Pipeline Insight, 2020 - Product Thumbnail Image

ALK-Positive Non-Small Cell Lung Cancer - Pipeline Insight, 2020

  • Clinical Trials
  • September 2020
  • 75 Pages
  • Global
From
From
Lorlatinib - Product Thumbnail Image

Lorlatinib

  • Report
  • August 2018
  • 16 Pages
  • Global
From
Alecensa - Product Thumbnail Image

Alecensa

  • Report
  • August 2018
  • 22 Pages
  • Global
From
Alunbrig - Product Thumbnail Image

Alunbrig

  • Report
  • August 2018
  • 16 Pages
  • Global
From
Disease Analysis: Non-Small Cell Lung Cancer (NSCLC) - Product Thumbnail Image

Disease Analysis: Non-Small Cell Lung Cancer (NSCLC)

  • Report
  • April 2021
  • 191 Pages
  • Global
Xalkori - Product Thumbnail Image

Xalkori

  • Report
  • August 2018
  • 19 Pages
  • Global
From
  • 10 Results (Page 1 of 1)
Loading Indicator

Xalkori (crizotinib) is a targeted therapy drug used to treat non-small cell lung cancer (NSCLC). It is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of a protein called anaplastic lymphoma kinase (ALK). This protein is found in some types of NSCLC and is associated with tumor growth. Xalkori is approved by the US Food and Drug Administration (FDA) for the treatment of metastatic NSCLC with ALK-positive tumors. It is also approved for the treatment of ROS1-positive NSCLC. Xalkori is a key drug in the lung cancer market, as it is the only approved therapy for ALK-positive NSCLC. It is also the only approved therapy for ROS1-positive NSCLC. Xalkori is a well-established drug, with a long history of clinical trials and a strong safety profile. The Xalkori market is highly competitive, with several major pharmaceutical companies competing for market share. These include Pfizer, Merck, AstraZeneca, and Novartis. Other companies, such as Boehringer Ingelheim, Daiichi Sankyo, and Eli Lilly, also have a presence in the market. Show Less Read more